Foghorn Therapeutics Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Foghorn Therapeutics Inc. | FHTX - NASDAQ |
$15.00-$17.00 | $16.00 | $19.00 | 7.5 million | 10/23/2020 |
| Goldman Sachs, Morgan Stanley, Cowen | ||||||
Co-Manager(s): Wedbush PacGrow | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-10-02 Terms Added 2020-10-19 | ||||||
Foghorn Therapeutics Inc. Quote & Chart - Click for current quote - FHTX
IPO Boutique aggregates information on public companies and private companies, such as "FHTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Foghorn Therapeutics Inc. (adapted from Foghorn Therapeutics Inc. prospectus):
They are pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "FHTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.